Arrhythmias & electrophysiologyCohort study
Impact of Downregulated Inflammation via the IL6R Asp358Ala Variant on Atrial Fibrillation Recurrence Following Ablation
- genetic association study
- IL6R Asp358Ala as a genetic proxy for IL-6 receptor blockade
- All of Us Research database
Authors' conclusion
Targeted IL-6 inhibition may have little impact on long-term AF recurrence in the general AF population undergoing ablation, although there may be potential benefit in heart failure patients.
Study context
- Population
- Patients undergoing atrial fibrillation (AF) ablation with genomic data in the All of Us Research databasepatients undergoing AF ablation · 1 copy of the Asp358Ala variant 707 · 2 copies 226
- Participants
- 1,540 patients
- Exposure
- Carriers of IL6R Asp358Ala vs noncarriers
- Outcome
- AF recurrence (composite of repeat AF ablation, cardioversion, or new class I/III antiarrhythmic drug, after a 3-month blanking period)
- Follow-up
- Median 1,317 days
Main finding
As reported in the abstract
Adjusted hazard ratio
0.93
95% CI 0.79–1.10
By group
carriers of Asp358Ala vs noncarriers
adjusted HR 0.93 (95% CI 0.79–1.10)
Observational data: associations, not effects.
Further findings
| Outcome | adjusted HR (95% CI) | |
|---|---|---|
| AF recurrence in patients with heart failure (subgroup) · heart failure subgroup (n = 312) | 0.72 (0.52–1.00) | |
| 0.512Adjusted hazard ratio (log scale) |
- AF recurrence in patients with heart failure (subgroup): interaction P = 0.049
AF recurrence, additive model (2 vs 1 vs no variant allele)
- No difference in recurrence; no dose-response with the variant
Original publication
Impact of Downregulated Inflammation via the IL6R Asp358Ala Variant on Atrial Fibrillation Recurrence Following Ablation. JACC Adv. Published 23 September 2026. doi:10.1016/j.jacadv.2026.103285
Summarised from the published abstract; every number is checked against it